Cartesian Therapeutics, Inc. — Director's Dealing 2017

Jul 10, 2017

SEC Form 4/A — Form 4/A

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2017-06-15

Reporting Person: Johnston Lloyd P. (COO and SVP, R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-15	Common Stock	M	10512	$0.47	Acquired	12118	Direct
2017-06-15	Common Stock	S	10512	$17.0416	Disposed	1606	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-15	Employee Stock Option (right to buy)	$0.47	M	10512	Disposed	2019-07-23	Common Stock (10512)	Direct

Footnotes

F1: On June 19, 2017, the reporting person filed a Form 4 reporting the June 15, 2017 exercise and sale of 20,512 shares of common stock pursuant to a 10b5-1 plan. The reporting person's broker subsequently acknowledged that 10,000 of such 20,512 shares were erroneously exercised and sold by the broker. The exercise and sale of the 10,000 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in their entirety, the transactions reported in the June 19, 2017 Form 4.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.10, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F4: All shares underlying this option are fully vested.